{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:58:54Z","timestamp":1794927534217,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1009"],"award-info":[{"award-number":["23FC1009"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008731","name":"Nakatomi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06964"],"award-info":[{"award-number":["JP23K06964"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K02371"],"award-info":[{"award-number":["JP24K02371"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K10629"],"award-info":[{"award-number":["JP25K10629"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004096","name":"Kyushu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jneuroim.2025.578799","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:19:49Z","timestamp":1762298389000},"page":"578799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy"],"prefix":"10.1016","volume":"410","author":[{"given":"Ayano","family":"Matsuyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuu-ichi","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578799_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","article-title":"The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations","volume":"18","author":"Acevedo","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000640","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0015","doi-asserted-by":"crossref","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0030","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jnnp-2024-334764","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD","volume":"96","author":"H\u00e4u\u00dfler","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0040","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0045","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"46","key":"10.1016\/j.jneuroim.2025.578799_bb0050","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.46.2400136","article-title":"Epidemiology of invasive meningococcal disease, Japan, 2013 to 2023","volume":"29","author":"Kobayashi","year":"2024","journal-title":"Euro Surveill."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0055","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martin\u00f3n-Torres","year":"2016","journal-title":"J. Adolesc. Health"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jnnp-2021-326386","article-title":"Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Masuda","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0065","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00415-023-11710-5","article-title":"High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder","volume":"270","author":"Moog","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105502","article-title":"Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: results from a Japanese claims database","volume":"84","author":"Nakashima","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105829","article-title":"Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan","volume":"90","author":"Niino","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0080","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0085","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u22654 years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis Optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0120","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1177\/1352458515600246","article-title":"Progressive cerebral atrophy in neuromyelitis optica","volume":"21","author":"Warabi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0125","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578799_bb0135","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0140","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40120-024-00640-7","article-title":"Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance","volume":"13","author":"Yamamura","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jneuroim.2025.578799_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106176","article-title":"The real-world impact of biologics for NMOSD: a retrospective single-center study compared with natural course and conventional treatments in Japanese","volume":"92","author":"Yamazaki","year":"2024","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:19:17Z","timestamp":1773310757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["S0165572825002802"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578799","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578799"}}